categorized regarding the specifics of the type of data requested. Using a comparative framework to examine the recommendations of CDR and NICE, we describe the frequency of the different types of data recommended for collection post-launch to highlight trends across jurisdictions RESULTS: Thirty-four of 64 CDR submissions recommended 'no listing', 17 'list with criteria', and 13 'list or list in similar manner as other drugs in the same category'. Of the 64 appraisals, 41 were recommended to conduct further research to either collect specific items of data (n = 28), conduct subgroup analysis (n = 13), or collect data using a more appropriate study design (n = 19). The most commonly requested item was long-term adverse events or safety data (16/28), and this observation is consistent with the fact that, to date, most post-launch studies are safety surveillance studies. In addition 11 of 28 recommended the collection of clinically important outcomes, long-term effectiveness (7/28). Similarly, 41 of 48 NICE appraisals recommended further research to collect real-world data, including treatment pathways, effectiveness, and long-term effectiveness or adverse events. CONCLUSION: This review suggests that recommendations for post-launch research from CDR and NICE appear to be similar. This highlights the inherent weakness of regulatory trials as a piece of evidence in informing reimbursement decisions. OBJECTIVE: To assess lifetime cost-effectiveness of glatiramer acetate (GA) compared to natalizumab (NZ) in patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) in the presence of long-term clinical evidence. METHODS: A literature-based Markov model was developed with patients transitioning through health-states based on Kurtzke expanded disability status scale (EDSS). Patients in the model are Ն21 years of age with RRMS and start in any of the health-states at diagnosis. Patients with an EDSS score below 6.0 receive treatment. Treatment effects for relapse and disease progression were obtained from clinical trials and long-term clinical evidence where available. Transition rates were estimated by applying a percent reduction of treatment effects of therapies to natural history rates of relapse and disease progression. Rates were adjusted for treatment discontinuation and persistent NZ antibodies. Patients incurred drug, other medical and lost worker productivity costs. Patients on NZ incurred additional costs for monitoring, diagnosis, and treatment of progressive multifocal leukoencephalopathy (PML), a possible serious adverse event for patients on NZ. Utility weights for each health-state were taken from published utility assessments for people with RRMS. The primary outcomes of the model were lifetime costs and qualityadjusted life years (QALYs). Costs (2005US$) and outcomes were discounted at 3% annually. RESULTS: The lifetime costs per patient for GA were $430,242 and for NZ were $498,728. QALYs during the lifetime of a patient on GA were 9.303 and 9.300 for a patient on NZ. The incremental cost per QALY for patients on GA and NZ compared to symptomatic treatment alone was $208,879 and $525,463 respectively. GA is costsaving when compared to NZ. PML had very little impact on results. CONCLUSIONS: While incorporating all the long-term clinical evidence, model results indicated that GA was both less costly and more effective over a patient's lifetime than NZ in treating RRMS.
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PHP18 HEALTH CARE DECISION-MAKERS' ATTITUDE ON HEALTH ECONOMICS RESEARCH
Galani Berardo C Institute for Medical Technology Assessment, Erasmus MC, Rotterdam, The Netherlands OBJECTIVE: To assess lifetime cost-effectiveness of glatiramer acetate (GA) compared to natalizumab (NZ) in patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) in the presence of long-term clinical evidence. METHODS: A literature-based Markov model was developed with patients transitioning through health-states based on Kurtzke expanded disability status scale (EDSS) . Patients in the model are Ն21 years of age with RRMS and start in any of the health-states at diagnosis. Patients with an EDSS score below 6.0 receive treatment. Treatment effects for relapse and disease progression were obtained from clinical trials and long-term clinical evidence where available. Transition rates were estimated by applying a percent reduction of treatment effects of therapies to natural history rates of relapse and disease progression. Rates were adjusted for treatment discontinuation and persistent NZ antibodies. Patients incurred drug, other medical and lost worker productivity costs. Patients on NZ incurred additional costs for monitoring, diagnosis, and treatment of progressive multifocal leukoencephalopathy (PML), a possible serious adverse event for patients on NZ. Utility weights for each health-state were taken from published utility assessments for people with RRMS. The primary outcomes of the model were lifetime costs and qualityadjusted life years (QALYs). Costs (2005US$) and outcomes were discounted at 3% annually. RESULTS: The lifetime costs per patient for GA were $430,242 and for NZ were $498,728. QALYs during the lifetime of a patient on GA were 9.303 and 9.300 for a patient on NZ. The incremental cost per QALY for patients on GA and NZ compared to symptomatic treatment alone was $208,879 and $525,463 respectively. GA is costsaving when compared to NZ. PML had very little impact on results. CONCLUSIONS: While incorporating all the long-term clinical evidence, model results indicated that GA was both less costly and more effective over a patient's lifetime than NZ in treating RRMS.
PHP19 IMMUNIZATION PROGRAM IN PARAGUAY: SOCIAL AND BEHAVIORAL DETERMINANTS AND ORGANIZATIONAL IMPACT
Maceira DA Center for the Study of the State and Society, Buenos Aires, Argentina OBJECTIVES: Public health care system in Paraguay is highly centralized, compared to other Latin American sectors, and more than half of the population relies on it in order to receive formal treatment. The National Immunization Program (EPI) is not an exemption, affecting the way local/departmental resources in immunization are allocated, impacting on the effectiveness of these investments. In addition, differences in population characteristics among departments, in terms of health care behavior, income and education, and the use of formal medicine patterns by original ethnic groups might affect EPIxs effectiveness. The goal of the paper is to identify how supply side characteristics (financial, managerial and immunization strategies) and demand side factors impact on immunization coverage. METHODS: The document proposes a sequential model, where local health authorities intent to fill the gap in immunization financing and managerial needs, based on the resources allocation and coverage strategy defined by the national health ministry, that leads the Paraguayan immunization design. As a result, a logistic model was implemented, where the likelihood of being vaccinated is tested as a dependent variable, where geographical, educational and ethnical barriers are checked. In addition, supply variables related to financing, coverage strategies and communicational efforts are included. The study analyze data from the Integrated National Household Survey (2001), complemented with a series of immunization effectiveness indexes constructed based on management, financing and vaccine provision criterion, distinguishing among financial sustainability, management effectiveness and antigen supply volatility, collected from official sources and interviews with key personnel by region. RESULTS: Health care policy variables were statistically significant, showing the relevance of social communication, measured in terms of physical, monetary and human resources involved. CONCLUSION: The paper shows the importance of socio-economic-cultural barriers on the probability of being immunized, based on health behavior, presence of formal health insurance, and main source of care (hospital, traditional medicine, etc.).
PHP20 THE GENERIC COST-EFFECTIVENESS OF HEALTH CARE
Meerding WJ, Mackenbach J Erasmus MC, Rotterdam, The Netherlands OBJECTIVES: To assess the generic cost-effectiveness of health care. METHODS: We estimated the contribution of prevention and medical care towards population health for infectious diseases, cancers, and cardiovascular diseases. This contribution was defined as the difference between the current burden of disease (BoD) and its counterfactual: a 'null' situation without selected prevention (vaccinations, screening, and preventive medication) and medical care, and accounting for the role of other health determinants such as improvements in housing and nutrition, and reduced smoking. The counterfactual was backcalculated with use of historical data on incidence, survival, mortality, and the prevalence of risk factors. The Global Burden of Disease methodology was applied, combining incidence, prevalence, mortality, and disability weights into multi-state lifetables. If required, epidemiological estimates were made internally consistent with advanced modelling techniques (DISMOD2). The difference between the current BoD and the counterfactual was combined with cost of illness data to estimate the generic cost-effectiveness of prevention and medical care for the selected disease clusters. RESULTS: The total increase in disability adjusted life expectancy due to prevention and medical care was 5.3 years: 1.7 years for infectious diseases, 0.6 years for cancers, and 3.1 years for cardiovascular diseases. This increase was larger for females than for males: 6.3 years and 4.3 years, respectively. The increase can be disentangled into an increase in life expectancy of 3.9 years and 1.4 decrease in years lived with disability. The average costs per DALY gained were 2,000 euro for cardiovascular disease, 3,400 euro for infectious diseases, and 16,000 euro for cancers. CONCLUSION: For the selected disease clusters, the average cost-effectiveness of health care is far below current acceptable thresholds. We assessed the likely health contribution of sociocultural and socioeconomic factors as opposed to health care with help of the best available knowledge, but many questions remain unanswered.
PHP21

IMPACT OF DISCONTINUITY IN HEALTH INSURANCE ON RESOURCE UTILIZATION
Shah ND, Banerjee R Mayo Clinic, Rochester, MN, USA OBJECTIVES: Public insurance for the poor (Medicaid) in the United States often results in poor continuity of coverage due to the phenomenon of "churning." Churning occurs when individuals lose and regain coverage in a short period of time. Gaps occur within the Medicaid program because of changes in family circumstances that make individuals ineligible for public insurance or because of administrative complexity that result in failure to renew coverage. The purpose of this study is to evaluate the impact of insurance transitions on health care utilization among the publicly insured non-elderly. METHODS: We used the Medical Expenditure Panel Survey (MEPS) for years [2000] [2001] [2002] [2003] [2004] for this study. MEPS provides monthly insurance status and resource utilization. Additionally, MEPS contains detailed demographic, socioeconomic and health status information. We estimated the number of transitions for an individual using monthly insurance data. We estimated resource utilization using the total number of inpatient hospitalizations, emergency room visits, outpatient visits, and total number of prescriptions. Number of inpatient hospitalization and emergency room visits were modeled using zero-inflated negative binomial models, while outpatient visits and prescription drugs were modeled using negative binomial models. RESULTS: Our sample has 35,779 individuals, of whom 10,754 had one transition into or out of Medicaid and 2,448 had more than one transition. We find that individuals with multiple transitions tend to have 46% more hospitalizations and use the emergency room 13% more. However, these individuals have 37% lower prescription drug utilization and 12% less outpatient physician visits relative to those who are continuously insured by Medicaid. CONCLUSION: Utilization of emergency and inpatient services were significantly higher, while use of outpatient care and prescription drugs was significantly lower for beneficiaries with interruption in Medicaid coverage. These findings point to the need for further research to assess the impact of churning in this population.
PHP22 THE GREEK PHARMACEUTICAL EXPENDITURE DATA: EFFECTS OF THE NATIONAL ACCOUNTS' REVISION
Kousoulakou H 1 , Kyriopoulos J 2 1 Foundation for Economic and Industrial Research, Athens, Greece, 2 National School of Public Health, Athens, Greece OBJECTIVES: In September 2006, the National Statistical Service of Greece revised the system of National Accounts. In this framework, significant increases took place in the data describing the pharmaceutical market, the overall picture of which has completely changed. The study aims to present these changes, as well as highlight some remarkable (or even questionable) characteristics of the revision. METHODS: Data from official sources relating to pharmaceuticals' production, external trade, expenditure and sales were collected and analyzed, in an effort to synthesize the overall picture of the pharmaceutical market and provide a comparative instrument for the revised data. RESULTS: Under the new data, the pharmaceutical market bears two significant changes: a) private pharmaceutical expenditure accounts for 47.5% of total expenditure-against 22% which was the case before the revision, and b) data on the demand side appear to exceed supply-side data-the latter including parallel exports. The disproportional rise in pharmaceutical expenditure (58% on average for the years [2000] [2001] [2002] [2003] [2004] [2005] led to an increase in pharmaceuticals' share to both health care expenditure and GDP. Moreover, the increase was totally attributable to a shift in private pharmaceutical expenditure-which was tripled-whereas public expenditure remained at the before-the-revision levels. However, such an increase contravenes both the fact that pharmaceuticals in Greece are mainly reimbursed by Social Insurance and the fact that the pharmaceutical market is heavily regulated and-in general-"hidden economy" phenomena do not exist. Furthermore, the increase is not supported by the results of the 2005 Household Budget Survey. CONCLUSION: The revised data raise questions on the relationship of public-private pharmaceutical expenditure and supply-demand market data, and entail the risk of leading to irrational decision making for both policy makers and pharmaceutical companies.
PHP23 RELATIONSHIP BETWEEN RISKS FOR LIFESTYLE-RELATED DISEASES AND MEDICAL EXPENSES AFTER 10 YEARS OF METABOLIC SYNDROME
Sakamaki H 1 , Kitazawa T 2 , Hasegawa T 2 1 Meijo University, Nagoya, Japan, 2 Toho University School of Medicine, Tokyo, Japan OBJECTIVES: This study was conducted to clarify the relationship between lifestyle-related diseases and medical expenses after 10 years of metabolic syndrome. METHODS: The subjects of analysis were 2165 people who were randomly selected from a population insured by the government-managed health insurance. The test results of 1993 were used to divide the subjects of analysis into the following 4 groups, and the diseases and medical expenses of each group were examined for 2003. Group 1 had no abnormality in any of the four test RESULTS: BMI, blood pressure, lipid levels, and glucose metabolism. Group 2 was not obese but had abnormality in one or more of the other three tested categories. Group 3 was only obese or obese and had abnormality in one of the other three tested categories. Group 4 had metabolic syndrome. In this study, the lifestyle-related diseases were diabetes, hypertension, hyperlipidemia, cerebrovascular disease, and ischemic heart disease. RESULTS: The risk of each lifestyle-related disease was examined by odds ratio adjusted by sex and age in comparing Groups 2, 3, and 4 with Group 1. The odds ratios of Groups 2, 3, and 4 were higher than that of Group 1. In Group 4, there were significant differences in all diseases. Analysis of covariance adjusted for sex and age was performed, and medical expenses were compared between each group. As a result, the total amount of annual medical expenses in 2003 was 52,470 yen for Group 1, 82,120 yen for Group 2, 72,720 yen for Group 3, and 109,660 yen for Group 4. The medical expenses were significantly higher in Group 4 compared with Group 1. CONCLUSION: The risks of lifestyle-related
